Almac Group Marks 50 Successful Years in Craigavon

Almac Group Marks 50 Successful Years in Craigavon

September 6, 2018

Organization reaches 5,000 employees globally

Craigavon, N.I., 6 Sept 2018 – Almac is celebrating 50 years since its founder, Sir Allen McClay, opened the doors of his pharmaceutical development business on its Craigavon headquarters.

The organization, which now operates in 17 locations across Europe, North America and Asia, was founded as Galen Limited in 1968. Following flotation on the New York, Dublin and London stock exchanges in 1997, Galen Holdings Plc became Northern Ireland’s first billion pound company.

When the company took a different path to that which Sir Allen had envisioned in 2001, he sold the majority of his shareholding and, in 2002, he founded the Almac Group.

Sixteen years later the campus at Craigavon serves as the organization’s global headquarters and houses seven Business Units and this year saw the recruitment of Almac’s 5000th employee globally.

Alan Armstrong, CEO and Chairman of the Almac Group said: “When he opened the doors of his business 50 years ago in Northern Ireland, Sir Allen had a vision of making a substantial contribution to healthcare across the globe.

“We are proud of our global reputation for excellence built over those 50 years. Our client service, scientific and operational expertise right across the drug development lifecycle offers a tailored solution to each of our clients. It is the dedication of our exceptional employees that enables us to provide this service and we pay tribute to their work as we reflect on the success of our company.

“We are excited about the future of our company. We look forward to making more exciting announcements as we reach new milestones and advancements across the business. As we look forward to continuing success, we wish to thank all those who have played their part in our story so far. So to our employees, clients, suppliers and other key stakeholders, thank you.”

The company’s most recently published financial figures show a 19% rise in revenue to £531m. It also reported an increase in pre-tax profits, up from £27m in 2016 to over £33m for the year ending 30 September 2017.

ENDS

About Almac Group
‘Partnering to Advance Human Health’

The Almac Group is an established contract development and manufacturing organization that provides an extensive range of integrated services to the pharmaceutical and biotech sectors globally. The services range from R&D, biomarker discovery development and commercialization, API manufacture, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.

The international company is a privately-owned organization that has organically grown over 50 years and now employs over 5,000 highly skilled personnel.

Almac is headquartered in Craigavon, Northern Ireland with 17 operations across Europe, the US (Pennsylvania, North Carolina and California) and Asia (Singapore and Tokyo).

Almac would like to acknowledge and thank all those organizations who have provided support over the last 50 years including Danske Bank, Invest NI, PWC and IDA.

To keep up to date with our latest news, follow us on Twitter and LinkedIn or visit almacgroup.com/50-years

Share

Back to news